Bristol-Myers Squibb Company, commonly known as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical giant headquartered in Princeton, New Jersey. As one of the world's largest pharmaceutical companies, BMS consistently ranks on the Fortune 500 list, securing the 98th position in 2024. The company is renowned for manufacturing prescription pharmaceuticals and biologics across various therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders. BMS's primary research and development (R&D) facilities are strategically located in Lawrence, New Jersey (formerly Squibb, near Princeton), Summit, New Jersey (formerly the headquarters of Celgene), New Brunswick, New Jersey, Redwood City, California, and Seville, Spain. The company also maintains R&D sites in Devens and Cambridge, Massachusetts, Braine-l'Alleud, Belgium, Tokyo, Japan, Hyderabad and Bangalore, India, and Wirral, United Kingdom. Historically, BMS had an R&D site in Wallingford, Connecticut. The roots of BMS trace back to 1858 when Edward Robinson Squibb founded the Squibb Corporation in Brooklyn, New York. Known for his advocacy for quality control and high purity standards in pharmaceuticals, Squibb's legacy laid the foundation for the company's commitment to excellence. In 1887, Hamilton College graduates William McLaren Bristol and John Ripley Myers acquired the Clinton Pharmaceutical Company and eventually renamed it Bristol-Myers Corporation after Myers' death in 1899. The pivotal merger of Bristol-Myers Squibb in 1989 gave rise to the current Bristol-Myers Squibb. BMS has expanded through strategic acquisitions, including Mirati Therapeutics in January 2024 for $4.8 billion plus $1 billion in milestone payments, and Karuna Therapeutics in March 2024 for $14 billion. These acquisitions, particularly Karuna's investigational antipsychotic KarXT, reinforce BMS's leadership in innovative pharmaceutical solutions.
The USP of Bristol lies in being one of the world’s largest pharmaceutical companies. Its mission statement states ‘To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.’ The vision is “To be the world's leading biopharma company that transforms patients' lives through science.”
Business Sector
Pharmaceuticals
Operating Geography
United States, North America, Global
Revenue
US$45 billion – FY ending 31st Dec 2023 (y-o-y decline of 2.3%)
US$46.1 billion – FY ending 31st Dec 2022
SWOT
SWOT Overview
Bristol Myers Squibb excels in innovation and new product development, supported by a strong focus on research and development, a diverse brand portfolio, and strategic alliances that fuel growth. The company has developed breakthrough solutions for various diseases and has experienced accelerated growth through acquisitions. However, it faces weaknesses such as revenue dependence on a few prioritised brands, a weak presence in the biologics segment, and major dependency on US and European markets. Opportunities for Bristol Myers Squibb include the growing cancer immunotherapy market, increasing globalisation in the pharma industry, and leveraging advanced digital technologies to transform healthcare. Threats include increasing competition from generic drug manufacturers, changes in US or foreign laws and regulations, and the loss of market exclusivity for its products. This SWOT analysis highlights Bristol Myers Squibb's strategic position, strengths, weaknesses, opportunities, and threats in the competitive pharmaceutical industry.
SWOT Matrix for Bristol Myers Squibb
Strength
Weakness
Innovation and rigorous new product development
Strong focus on research and development
Strong and diverse brand portfolio
Complimentary alliances for fueling growth
Breakthrough solutions developed for diseases
Accelerated growth driven by acquisitions
Revenue dependence on a few prioritised brands
Weak presence in the biologics segment
Major dependency on US and European markets
Opportunity
Threat
Growing cancer immunotherapy market
Increasing globalisation in the pharma industry
Leverage advanced digital technologies to transform healthcare
Increasing competition from generic drug manufacturers
Changes in US or foreign laws and regulations
Loss of market exclusivity of the products
Detailed SWOT Analysis of Bristol Myers Squibb
The detailed SWOT analysis for Bristol Myers Squibb is presented below:
Strength
Innovation and rigorous new product development: Bristol-Myers Squibb is known for its innovative capabilities to discover, develop and deliver transformational medicines. It has achieved significant research breakthroughs in therapeutic areas such as Oncology, Immuno-science, Cardiovascular, and Fibrosis. It continued to introduce new medicines in 2023, including Reblozyl for anaemia in adult patients and Opdivo in Japan. During the year, it also reached significant clinical and regulatory milestones across its portfolio, expanding the potential of Zeposia and introducing it as the first oral treatment for ulcerative colitis.
Strong focus on research and development: BMS has maintained its status as one of the most innovative pharma companies by investing heavily in R&D. The R&D expenses were US$9.3 billion in 2023, US$9.5 billion in 2022 and US$10.2 billion in 2021, showing a strong trend, while the acquired IPRD expenses were US$913 million in 2023, rising from US$815 million in 2022. In 2023, the company also opened a research facility in Hyderabad, India with a US$100 million investment, and it will construct a new R&D facility in Cambridge, Massachusetts. Additionally, it is enhancing its manufacturing capabilities by erecting brand-new cutting-edge cell therapy manufacturing facilities in Devens, Massachusetts, and Leiden, the Netherlands, in support of its ongoing investment in its cell therapy portfolio. BMS had approximately 40 unique assets in clinical development as of Feb 2024.
Weakness
This section is available only in the 'Complete Report' on purchase.
Opportunity
This section is available only in the 'Complete Report' on purchase.
Threat
This section is available only in the 'Complete Report' on purchase.
PESTLE
PESTLE Overview
Bristol Myers Squibb faces a dynamic environment shaped by various political, economic, social, technological, legal, and environmental factors. Politically, the US-China trade war impacts the pharma industry, and there is rising support for biosimilars in the U.S. Economically, the company navigates currency market fluctuations and global economic uncertainty. Socially, the ageing global population and the increase in lifestyle-related diseases drive demand for healthcare solutions. Technologically, there is a proliferation of digital health technologies, rapid advancements in analytics, and integration of automation and virtual reality in manufacturing. Legally, changes in IP protection laws and efforts to reduce counterfeit drugs impact the industry. Environmentally, Bristol Myers Squibb aligns its corporate vision with sustainable development to address climate change. This PESTLE analysis mirrors Bristol Myers Squibb's strategic position and the external factors influencing its operations.
PESTLE Matrix for Bristol Myers Squibb
Political
Economic
Impact of the US-China trade war on pharma
Rising support toward biosimilar and other drugs in the US
Fluctuations in currency market
Impact of global economic uncertainty
Social
Technological
Continued ageing of the global population
Increase in lifestyle-related diseases
Proliferation of digital health technologies
Rapid upsurge in the advanced analytics technology
Integration of automation and virtual reality in manufacturing plants
Legal
ENVIRONMENTAL
Changes in IP protection laws
Laws to reduce the circulation of counterfeit drugs
Corporate vision aligned with sustainable development to address climate change
Detailed PESTLE Analysis of Bristol Myers Squibb
The detailed PESTLE analysis for Bristol Myers Squibb is presented below:
POLITICAL
Impact of the US-China trade war on pharma: The US-China trade war has significantly impacted the pharma industry, disrupted supply chains, and increased costs for raw materials and active pharmaceutical ingredients (APIs). Many pharmaceutical companies rely on Chinese manufacturers for APIs, making tariffs and trade restrictions particularly challenging. The uncertainty and geopolitical tensions have led to increased scrutiny and the need for diversification of supply sources, potentially slowing down drug production and innovation. Additionally, regulatory hurdles and compliance requirements have become more stringent, adding to operational complexities and costs. The trade war has also spurred investments in local manufacturing to mitigate dependency on Chinese suppliers. Amendments of the Biosecure Act by the US in 2024 exemplify the risk that pharma companies have to face, these companies, including Bristol-Myers Squibb, are looking to mitigate the risk by focusing on diversifying its supply. For the company, the trade war adds pressure to secure reliable and diversified supply chains, potentially increasing operational costs and impacting global drug production efficiency.
ECONOMIC
This section is available only in the 'Complete Report' on purchase.
SOCIAL
This section is available only in the 'Complete Report' on purchase.
TECHNOLOGICAL
This section is available only in the 'Complete Report' on purchase.
LEGAL
This section is available only in the 'Complete Report' on purchase.
ENVIRONMENTAL
Corporate vision aligned with sustainable development to address climate change: Climate change and environmental sustainability are increasingly crucial issues for the pharmaceutical industry. With the sector's significant environmental impact through high energy consumption, waste production, and pollution, companies are under pressure to adopt sustainable practices. Efforts are being made to reduce greenhouse gas emissions, manage waste, and utilize renewable energy sources. These initiatives not only aim to mitigate environmental damage but also to enhance the industry's reputation and operational efficiency?. For Bristol-Myers Squibb, the focus on environmental sustainability translates into setting ambitious targets such as achieving 100% renewable energy consumption by 2030 and net-zero emissions by 2050. These efforts help the company align with global sustainability goals and reduce its environmental footprint, fostering a positive corporate image and long-term viability?.
More Info
Major Competitors
Merck & Co., Inc. (MRK)
AbbVie (ABBV)
Pfizer (PFE)
Zoetis (ZTS)
Royalty Pharma (RPRX)
Jazz Pharmaceuticals (JAZZ)
Perrigo (PRGO)
Corcept Therapeutics (CORT)
Supernus Pharmaceuticals (SUPN)
Pacira BioSciences (PCRX)
Table of Contents
Company Overview
1.1 About the Company
1.2 Business Sector
1.3 Operating Geography
1.4 Revenue
SWOT Analysis
2.1 SWOT Table/ SWOT Matrix
2.2 SWOT Overview
2.3 Detailed SWOT Analysis
2.4 Strength, Weakness, Opportunity and Threat
PESTLE Analysis
3.1 PESTLE Table/ PESTLE Matrix
3.2 PESTLE Overview
3.3 Detailed PESTLE Analysis
3.4 Political, Economic, Social, Technological, Legal and Environmental
You can use the following in your reference section to
give credit to the source. For different referencing
styles and detailed guidelines, please
click here
The detailed complete set of references is available on request in the 'Complete report' on purchase.
Bristol Myers Squibb SWOT and PESTLE analysis has been conducted by Sindhu and reviewed by senior analysts from Barakaat Consulting.
Copyright of Bristol Myers Squibb SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.
The reports published by SWOT & PESTLE.com are created under a stringent life cycle which undergoes data validation checks and quality surveillance at each of the stages of data procurement, identification, selection, processing, extraction and analysis. Earnest efforts are made to capture and validate the quality and preciseness of data. Our analysts by and large use the following sources to put together valuable analytical research reports:
Company annual reports and SEC filings (10-K, 20-F, 10-Q etc)
Company official portal
Investors presentations
Research reports of key industry players/competitors
Historical data
Data from government sources
Media releases which include journals, published literature, press releases, market information that cover industry news, country news, and customer intentions.
An aggregation of the experiences, expertise and insights of our analysts who go through volumes of data to extract meaningful information.
Why Choose Us?
Other Analysis
Related Report
Recently Viewed
Delivery Within * 1 Hour
This report contains the table contents only. In case you
need the complete report please purchase using the buy
options displayed.
This is the sample complete report which will give you a
glimpse of what your complete report will cover after
purchase.
Get the report (PDF) delivered to your email within minutes.
** Get the report (PDF) sent to your email within
minutes
The illustrative sample reports are shared in order to give
you an idea of what the SWOT & PESTLE Report for Bristol Myers Squibb will cover
after purchase. We invest deep in order to bring you
insightful research which can add tangible value to your
business or academic goals, at affordable pricing.
Value Subscription Plans
Subcription Plans start with as low as $53
Custom Research Reports
Are you looking for a report which is customised to
align with your business needs?
Our custom research services provide incisive
competitive acuity you need to dig In to the right data
and provide actionable insights decisions for your
business.
Our experienced analysts and
consultants will ensure comprehensive coverage and
tailor it to best fit your needs.
Please note that custom research reports have a
delivery period anywhere between
1 to 5 business days.
Delivery Within * 1 Hour
Bristol Myers Squibb SWOT & PESTLE
In case you want this report emailed straight into your email
inbox, kindly share your details below. Please note that you agree
to receive email updates from us on our new reports and solutions.
